Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial

IMPORTANCE: Phosphodiesterase-5 inhibition with sildenafil compared with a placebo had no effect on the exercise capacity or clinical status of patients with heart failure with preserved ejection fraction (HFpEF) in the PhosphodiesteRasE-5 Inhibition to Improve Clinical Status and Exercise Capacity...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JAMA Cardiol
Egile Nagusiak: Wang, Hanghang, Anstrom, Kevin, Ilkayeva, Olga, Muehlbauer, Michael J., Bain, James R., McNulty, Steven, Newgard, Christopher B., Kraus, William E., Hernandez, Adrian, Felker, G. Michael, Redfield, Margaret, Shah, Svati H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Medical Association 2017
Gaiak:
Brief Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5815079/
https://ncbi.nlm.nih.gov/pubmed/28492915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2017.1239
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak